|
Irving Weissman |
Stanford University |
Phase 1 |
Completed |
88 |
|
|
Anthony Gringeri |
ImmunoCellular Therapeutics |
Phase 3 |
Suspended |
234 |
|
|
Christine Brown |
City of Hope, Beckman Research Institute |
Phase 1 |
Active, not recruiting |
82 |
|
|
Saul Priceman |
City of Hope, Beckman Research Institute |
Phase 1 |
Recruiting |
39 |
|
|
Leo Wang |
City of Hope, Beckman Research Institute |
Phase 1 |
Recruiting |
18 |
|
|
Crystal Mackall |
Stanford University |
Phase 1 |
Recruiting |
54 |
|
|
Jana Portnow |
City of Hope, Beckman Research Institute |
Phase 1 |
Launching |
N/A |
|
|
Mark Chao |
Forty Seven Inc. |
Phase 1/2 |
Completed |
78 |
|
|
Ivan King |
Tachyon Therapeutics, Inc |
Phase 1 |
Launching |
N/A |
|
|
Steven Dubinett |
University of California, Los Angeles |
Phase 1 |
Recruiting |
24 |
|
|
Robert Dillman |
Caladrius Biosciences |
Phase 3 |
Closed |
4 |
|
|
Antoni Ribas |
University of California, Los Angeles |
Phase 1 |
Recruiting |
12 |
|
|
Theodore Nowicki |
University of California, Los Angeles |
Phase 1 |
Recruiting |
12 |
|
|
Dennis Slamon |
University of California, Los Angeles |
Phase 1 |
Completed |
46 |
|
|
Pamela Contag |
BioEclipse Therapeutics INC. |
Phase 1 |
Recruiting |
24 |
|